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The HYP-RT model simulates hypoxic tumour growth for head and neck cancer as well as radiotherapy and the eﬀects of
accelerated repopulation and reoxygenation. This report outlines algorithm design, parameterisation and the impact of accelerated
repopulation on the increase in dose/fraction needed to control the extra cell propagation during accelerated repopulation.
Cell kill probabilities are based on Linear Quadratic theory, with oxygenation levels and proliferative capacity influencing cell
death. Hypoxia is modelled through oxygen level allocation based on pO2 histograms. Accelerated repopulation is modelled by
increasing the stem cell symmetrical division probability, while the process of reoxygenation utilises randomised pO2 increments
to the cell population after each treatment fraction. Propagation of 108 tumour cells requires 5–30 minutes. Controlling the extra
cell growth induced by accelerated repopulation requires a dose/fraction increase of 0.5–1.0Gy, in agreement with published
reports. The average reoxygenation pO2 increment of 3mmHg per fraction results in full tumour reoxygenation after shrinkage
to approximately 1mm. HYP-RT is a computationally eﬃcient model simulating tumour growth and radiotherapy, incorporating
accelerated repopulation and reoxygenation. It may be used to explore cell kill outcomes during radiotherapy while varying key
radiobiological and tumour specific parameters, such as the degree of hypoxia.
1. Introduction
Multiple studies have shown that hypoxia decreases cellular
sensitivity to ionising radiation in living tissue. Consequent-
ly, there is an increase in radioresistance of hypoxic tumour
cells following single or multifraction radiotherapy com-
pared to oxic cells. Approximately 70% of locally advanced
head and neck squamous cell carcinomas (HNSCC) have
been reported to exhibit hypoxic regions, with median
oxygen levels having a significant influence patient prognosis
[1–3]. Reports from HNSCC clinical trials and experimental
work commonly express hypoxia as the percentage of cells in
the tumour having pO2 values less than 10, 5, or 2.5mmHg,
which is often very high (>50%) [4, 5]. In contrast, the
average pO2 for healthy epithelial cells is approximately
40mmHg [5].
Tumour hypoxia occurs when the diﬀusion of oxygen
from the surrounding tissue becomes insuﬃcient in a nonva-
scularised tumour mass. It has been shown that tumours can
grow up to a diameter of 1 to 2mm without an independent
blood supply [6, 7], after which neovascularisation is neces-
sary for sustained growth. However, the new blood vessels
may be chaotic in nature and possess faults such as holes and
shunts. Consequently, an unstable and insuﬃcient oxygen
supply may develop causing tumour hypoxia. However,
when a tumour is treated with fractionated radiotherapy,
oxygen levels may begin to increase again during the process
of tumour shrinkage, a phenomenon named reoxygenation
(ROx).
In aggressive tumours of epithelial origin such as
HNSCC, cellular repopulation after trauma such high-dose
irradiation, occurs through cell division of the surviving cell
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population. This repopulation can occur at an increased rate,
a phenomenon named accelerated repopulation (AR). AR
can have a detrimental impact on radiotherapy outcome,
especially if the total treatment time is relatively long [8].
Multiple published HNSCC clinical trial reports conclude
that the onset time of AR, or the so-called kick-oﬀ time, is
between 2 and 5 weeks [8–12] after the start of treatment.
As a supplement to clinical trials, Monte Carlo (MC)
models can provide treatment response predictions which
are (i) readily obtained and low in cost, (ii) reproducible,
(iii) have the ability to account for the statistical nature of
cellular kinetics and radiotherapy physics, and (iv) tumour
specific depending on the data input into the model. MC
methods and modern computing technology now make it
possible to simulate the progression of individual tumour
cells throughout the growth and treatment of a tumour
approaching clinical sizes.
The first reported computer model to employ MC
methods was named CELLSIM by Donaghey and coworkers,
published in the early 1980s [13]. One of the first models to
include cellular-based stochastic methods as well as oxygen
and nutrient diﬀusion factors came from work led by
Dutching in the early 1980s and into the following decade
[14–17]. Using their approach, a tumour up to 1mm in
diameter could be simulated and then treated with radio-
therapy. Recent reports regarding stochastic hypoxic tumour
modelling over that past two decades have come from work
by group leaders such as Kocher, Titz, Borkenstein, and
Stamatakos [18–24], in which the modelling of individual
cells and hypoxia-related parameters have been applied.
The HYP-RT model reported on here is based on
the biological proliferative hierarchy of epithelial tissue to
simulate oxic as well as hypoxic head and neck squamous
cell carcinoma evolution. Cell division is tracked throughout
growth and fractionated radiotherapy. HYP-RT takes into
account the reoxygenation process of hypoxic tumours and
the increased proliferation caused by accelerated repopula-
tion. Stem cell symmetrical division is applied as the sole
mechanism of AR, that is, the division of a stem cell into
two daughter stem cells, based on reports of the dominance
of this mechanism over other mechanisms such as cell
cycle time shortening [8, 25]. A nonspatial approach in this
probabilistic model means that cells are considered randomly
placed within the tumour which is a justified approach
considering that hypoxic tumour cells have been shown
in multiple studies to be spatially irregular down to the
submillimeter level, for example, in immunohistochemistry
studies [26]. Compared to other models in the literature,
HYP-RT has the benefits of fast computation, a high cell
number, simple oxygenation data input in the form of a pO2
histogram, and the simulation of the combined eﬀects of AR
and ROx.
The aim of the current modelling work was to extend the
previous hypoxic tumour growth algorithm [27] and simu-
late conventionally fractionated radiotherapy. Improving the
cell data storage and random cell selection aspects of the
algorithm was also a goal, so that a full simulation could be
completed in less than one hour. It was also important to
model a suﬃcient cell number to surpass the approximate
avascular exponential growth phase (106 cells [28]) and reach
a cell number approaching clinical levels, that is, 108-109
cells, while achieving statistically stable results (≤5%).
This report outlines themethodology of the radiotherapy
eﬀect algorithm and discusses the key parameters of the
model. Focus is placed on the ROx and AR modules of
the algorithm and the eﬀects of varying related parameters
during simulations. The model is validated for the oxic
tumour case through a comparison with linear quadratic
(LQ) theory. The current work builds on a previous detailed
description of the original hypoxic tumour growth algorithm
[27] and the recently published conventional radiotherapy
model outcomes [29] using the default parameters defined
in the current report. In the following sections, modelling
methods and algorithm design are detailed, along with the
validation of modelling AR by means of increasing the stem
cell symmetrical division probability and the consequential
rise in dose per fraction needed to control the extra cell
growth.
2. Methods
2.1. The Tumour Growth Algorithm. Carcinogenesis is ini-
tiated through cell division of a single oxic stem cell. Cell
proliferation and subsequent tumour progression have been
modelled by the continual division of cells into one or two
viable daughter cells, with attributes allocated and saved to
computer memory in an object vector array referred to as
the cellarray The current data storage method diﬀers from
the two dimensional array methods previously reported.
Methods were modified to allow for more eﬃcient data
storage that is 100% memory eﬃcient at the time of
tumour growth completion and enhanced eﬃciency relating
to random sampling procedures.
In the model, each element in the cellarray represents one
cell object containing all cellular attributes as well as a pointer
value indicating the position of the next chronological cell
due to divide (the linked list method). MC methods are
implemented to allow the random nature of the cellular
kinetics and the eﬀects of radiation treatment to be sim-
ulated using probability distributions. Cellular parameters,
such as cell cycle time (CCT) and the cell type, resulting
from mother cell division and the diﬀerentiation process,
are allocated based on random number generation using
uniform, normal, or exponential probability distributions
and the Ziggurat random number generator [36].
Stem cells (S) first pass through the G0 quiescence
phase with an exponential probability of duration and then
enter the cell cycle. These cells are considered clonogenic
and infinitely proliferating; however they may diﬀerentiate
upon division or enter state of quiescence induced by low
oxygenation. Other types of cells in the model include
transit amplifying cells that cycle for a limited number of
generations (T cells), diﬀerentiating cells (D1 and D2 cells),
as well as fully diﬀerentiated cells (D3 cells). Stem cells may
divide into S, T, or D1 cells, while transit cells may divide into
D1 or D2 cells. In normal epithelium, the D1 cells correspond
to those created in the basal layer, while D2 to those created
Computational and Mathematical Methods in Medicine 3
Table 1: Default parameter values and ranges available in the tumour growth algorithm.
Parameter Default References Comments
Cell total 108 N/A The fully grown tumour cell limit.
Spercent, symmetrical stem cell division
probability (%)
3% N/A
This parameter was set to produce a 1% total stem
cell population in the tumour.
Low oxygen limit for cell cycle arrest
(mmHg)
1mmHg [43, 44]
At this pO2 level hypoxia-induced quiescence may
be initiated.
Percentage of cells exiting the cell cycle
(with pO2 <1mmHg) (%)
50% N/A
The total number of hypoxia-induced quiescent
cells (<1mmHg) = 3% using this parameter
value, in line with the pO2 histogram used.
Tumour cell number threshold for
hypoxia
106 [6, 7, 28, 45]
Hypoxia is modelled after the cell number is
reached by allocating pO2 from the modelled pO2
histogram.
Hypoxic cell half life due to necrosis:
pO2 < 1mmHg (days)
4 days [46, 47]
Due to the 4- to 10-day hypoxic cell lifetime in
human colon carcinoma spheroids, and 2 days in
xenograft HNSCC.
above the basal layer. The percentages of each cell type in
the model were verified as biologically plausible based on
experiment epithelial tissue reports and other modelling
studies [37–39].
The parameter Spercent controls symmetrical stem cell
division and represents the probability of a stem cell dividing
into two daughter stems cells. This parameter was assigned
a default value of 3.0%, which was based on achieving a
total stem cell population of approximately 1% [27], a
diﬀerentiated cell population of approximately 85% [37, 38],
and an average tumour doubling time of 50 days [40]. Note
that doubling times for tumour of diﬀering oxygenation
levels fell within a 35- to 65-day range.
Due to the high percentage (85%) of noncycling cells
required to ensure suitable tumour growth rates, the mod-
elled tumours may be roughly equated to mid- to well-
diﬀerentiated HNSCC disease. This is in contrast to poorly
diﬀerentiated tumours. However, this distinction is diﬃcult
to quantify. The modelling of tumours exhibiting specific
levels of diﬀerentiation was not a goal of the current work,
nor was the interplay between the number of diﬀerentiated
cells and tumour oxygenation status.
The oxygenation of oxic tumours utilises a uniform pO2
distribution, ranging from 5 to 100mmHg. These pO2 limits
were set due to 5mmHg often being used in published clini-
cal trial reports as a hypoxic threshold and due to 100mmHg
[41] being the highest value measured experimentally in
HNSCC Eppendorf studies. To model a biologically relevant
range of tumour cell pO2 values for head and tumours,
normalised data from Eppendorf studies [5, 41, 42] were
implemented using a log-normal function and a random
number algorithm written by J. Filliben (1982).
Tumour growth parameters values were set using bio-
logical data from the literature (e.g., oxygen distribution).
If this was not possible, the model was used to explore
the relative eﬀects of certain parameters on other variables
and parameters during the growth and treatment process
(e.g., ROx increment size during radiotherapy). Key growth-
related parameters and associated references are presented in
Table 1.
Table 2: Tumour oxygenation histogram data for the three
modelled oxygenation levels, indicating the modelled percentage of








0 to 2 2.1 7.3 9.4
0 to 5 5.2 22.1 33.2
0 to 10 10.4 45.6 54.5
0 to 20 20.8 65.4 69.6
To implement tumour hypoxia, a pO2 probability dis-
tribution is used to allocate values to daughter cells. For a
mother cell producing only one cell, the mother cell pO2
is passed to the daughter cell. When two daughter cells are
generated, one cell is randomly chosen to retain the mother
cell pO2 and the other receives a new pO2 value from the
distribution.
The first hypoxic pO2 distribution modelled is named
moderate hypoxia. A second pO2 distribution representing a
tumour with more severe hypoxia is also modelled. The
severe hypoxia pO2 distribution is generated to achieve a
relatively high number of cells in the low pO2 range
(<10mmHg) compared to moderate hypoxia and is tested
in the model for the impact on tumour growth rate.
Distributions with a higher (>3%) percentage of cells below
1mmHg result in tumours that are too hypoxic and result in
tumour shrinkage instead of growth. Both pO2 distributions
along with published data are shown in Figure 1(a). Numeric
histogram data for published versus modelled percentages of
cells in diﬀerent pO2 ranges are presented in Figure 1(b) and
Table 2.
Cellular pO2 influences CCT [43, 48], implemented
using an exponential function to slow the cell cycle with
decreasing pO2. To account for the eﬀects cell quiescence due
to very low oxygenation, a threshold value of 1.0mmHg is
applied. These quiescent cells then die with a half life value of
4 days unless subsequently reoxygenated. As some cells have
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(b) Oxygenation Statistics in Human Head and Neck tumours.
Figure 1: The distribution of tumour oxygen levels used (a) to simulate moderate and severe tumour and (b) in simulations (sim) compared
to published data for three oxygenation ranges [4, 30–35]. The distributions in (a) represent the pO2 histogram outputs from themodel using
a log-normal random number generator.
been shown experimentally to continue cycling even at very
low oxygenation levels through anaerobic metabolism, only
a percentage of cells with pO2 of less than 1mmHg are made
quiescent. The percentage for this parameter was determined
by trial and error and ensuring that the total population of
cells with this very low oxygenation corresponded with the
log-normal pO2 distribution at the 0 to 1mmHg level (3%).
An analysis of the growth algorithm was performed to
analyse the eﬀects of the symmetrical stem cell division
probability (Spercent) on tumour growth rate (doubling
time, TD) and total growth time. This was carried out for oxic
and hypoxic tumours, with the cell types in the population
being validated. All of the current modelling work was
programmed in the FORTRAN95 programming language
within the Microsoft Visual Studio framework (2003).
2.2. The Radiotherapy Algorithm. The radiotherapy algo-
rithm was developed to simulate the eﬀects of fractionated
therapy, assuming that a uniform dose is delivered to all
cells. LQ theory is used to define the average cycling cell
survival probability using the standard surviving fraction
(SF) equation based on alpha and beta parameters. This is
calculated for each cell individually for each dose fraction
in the schedule. For example, using alpha and beta values of
0.3 and 0.03, respectively (α/β = 10Gy), and a standard 2Gy
per day treatment schedule, the SF value is 48.7%. However,
this calculation is adjusted for the individual cell based on
the cellular pO2. The adjustment is based on the oxygen
enhancement ratio (OER) (1), which is implemented in the
program by normalising the OER curve to a maximum value








1 + 0.324 pO2
0.616
) . (1)
For each fraction, all cells in the cellarray are chronologically
assessed to determine if they will survive or die. Figure 2 rep-
resents the relationship between (a) OER and pO2 (mmHg)
and (b) probability of lethality and pO2 (mmHg) used in the
model. Note that the eﬀect of the actual dose being delivered
is not shown in Figure 2, only the influence of pO2 on cell
death when a specific dose per fraction is applied [50, 51].
To model the gradual rise in tumour oxygenation during
treatment, pO2 increments (3mmHg) are distributed to the
cell population at set time intervals. During reoxygenation
events, a percentage of cells have their pO2 values increased
by one or more pO2 increments, that is, by 0, 3, 6, 9, or
12mmHg. Events are set to occur a few hours after each
treatment fraction (default value of 4 hours [44]). The
number of cells randomly chosen to receive the various








1− p)n−k , (2)
where n is the total number of oxygen increments (equal to
the number of cells in the population at the current time),
k is the number of pO2 increments applied to a cell, and Pk
is the probability of a cell receiving a k × 3mmHg increase
in pO2. The probability of five or more increments is below
0.5% and regarded as negligible.
Default parameters in the ROx algorithm were set
through observation of the rate at which hypoxia-induced
quiescent cells were brought back into the cell cycle and
the rate of change of the resulting pO2 histograms from the
cycling cell population. Oxygen increment size was set by
default to ensure that tumours shrink to between 105 and
106 cells (1mm in diameter) with a final pO2 histogram
resembling a uniform oxic distribution with all pO2 values
≥5mmHg.
Cells assigned to quiescence due to hypoxia (pO2 <
1mmHg) have a probability of having their pO2 levels
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(b) The factor used to reduce the probability of cell death versus pO2 and
dose per fraction.
Figure 2: (a) Oxygen Enhancement Ratio (OER) curves implemented in the model for adjusting the radiosensitivity of cells during
radiotherapy, based on cellular pO2 and dose per fraction, and (b) conversion of the OER curves into a probability of cell death factor,
through OER curve normalisation.
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Figure 3: A flow diagram of the fractionated radiotherapy algorithm, where initiation of treatment is followed by continual cell proliferation
between dose fractions.
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Table 3: A list of model parameters used in the fractionated radiotherapy algorithm.
Parameter Default References Comments
Accelerated repopulation (AR)—time of onset
after initialisation during RT (weeks)
No onset [8, 10–12, 25, 53–55]
The number of weeks into RT that AR is
onset, 2–4 weeks observed in literature;
however 0 week onset has been made
possible for modelling microscopic response
in a small tumour system.
Reoxygenation (ROx)—time of onset after
initialisation during RT (weeks) No onset N/A
An extremely variable parameter and open
to user input.
Time of ROx after a particular RT fraction
(weeks)
4 hours [44]
AR boost factor ×10 [23, 25, 40]
The factor applied to increase the
symmetrical stem cell division probability
during AR.
ROx-induced incremental increases in pO2
(mmHg)
3mmHg N/A
The pO2 increment size during randomised
reoxygenation after an RT fraction (linearly
SF dependent), set to obtain full
oxygenation by ∼1 to 2mm tumour
diameter.
ROx percentage of the very low oxygenated cell
population (%)
60% N/A
The percentage of hypoxia-induced
quiescent cells brought back into the cell
cycle upon ROx after an RT fraction
(linearly SF dependent), set to obtain full
oxygenation when the tumour has reduced
to 105 to 106 cells (from 108 initial cells).
Alpha (LQ model) Gy−1 0.3 [56, 57]
Used in SF calculations (linear quadratic
equation).
Beta (LQ model) Gy−2 0.03
Used in SF calculations (linear quadratic
equation).
Noncycling cell radiosensitivity compared to
oxic cycling cells
0.5 [58, 59]
Factor for the decreased radiosensitivity of
noncycling cells, based on the likely increase
in resistance of cells in resting phase (transit
cells and stems cells however assumed to be
equally radiosensitive in tumour cells).
increased using a parameter to control the percentage of cells
to be retrieved from the quiescent group and reentered into
the cellarray that stores the cycling cells.
Accelerated repopulation is modelled by increasing the
Spercent variable by a multiplicative factor (the AR boost
factor) to simulate rapid tumour regrowth. As the range of
possible onset times of AR varies in literature reports, a
range of 0 to 3 weeks is analysed. This time range covers
the possibility of immediate cell response as well as the latest
onset time to have eﬀect on total dose outcomes in themodel.
The default AR boost factor is based on a study of the
extradose required to kill the cells that exist due to AR.When
simulating no AR eﬀects in oxic tumours 30× 2Gy (6 weeks
of treatment) is required to control a tumour, therefore for
all AR- and ROx-related simulations the eﬀects of AR are
calculated using 6 weeks at the iso-eﬀect total treatment
time. The duration of treatment for total cell kill was then
compared to the 6-week standard time and the extradose per
fraction required calculated for each simulation. Note that
the extradose per fraction applies only during the weeks in
which AR is occurring. The extra dose per fraction, d, is









where BED is the total dose required from simulations to
kill all cells after onset of AR, α/β =10Gy, and n is the
number of fractions for which AR is applied [52]. The
default irradiation schedule used in the treatment module
for this work is the conventional 2Gy per day, 5 day per week
dose schedule. Figure 3 outlines the flow of the radiotherapy
algorithm. The key parameters utilised in the model to
simulate ROx and AR during radiotherapy are outlined in
Table 3.
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Tumour cell type population percentages versus
the symmetrical stem cell division probability (spercent)
Figure 4: The average percentage of cell types within simulated
tumours of 108 cells, where (a) the symmetrical stem cell division
probability parameter, Spercent, has been varied from 2 to 30%
(standard deviation <1%).
3. Results
All tumour growth simulation results apply to 108 cell virtual
tumours. The results summarise the impact of the Spercent
parameter on growth rate and cell types percentage and
verify that the modelling of hypoxia does not change the cell
population structure, as intended. Treatment results relate to
verification of the default AR boost factor for diﬀerent AR
onset times for both oxic and hypoxic tumours. Hypoxic
tumour results are also presented for simulations varying the
hypoxia-induced quiescent cell death half-life. Note that it
may be possible for tumour cell of any proliferative capacity
to avoid radiation cell kill due to hypoxia and become
reoxygenated after treatment, contributing to local tumour
recurrence. Moreover, hypoxia may cause mutations in the
tumour cell population including dediﬀerentiation which
may result in more aggressive tumour growth [60, 61].
Consequently, although survival of only the stem cells is
traditionally considered to result in treatment failure, the
number of fractions required to kill all stem, transit, and
first-generation diﬀerentiating cells is presented.
Hypoxic tumour radiotherapy results use the moderately
hypoxic pO2 distribution shown in Figure 1(a). Severely
hypoxic tumours with a higher number of cells in the 0 to
10mmHg range were alsomodelled, but results did not diﬀer
significantly from moderately hypoxic results. This issue will
be investigated in future work to discern the necessary change
in the shape of the pO2 curve (peak width and peak height)
required to obtain statistically diﬀerent outcomes for very
hypoxic tumours.
3.1. Tumour Growth Analysis and Algorithm Eﬃciency. The














(a) Oxic vs. moderately hypoxic tumour doubling time (TD) versus the
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(b) Oxic vs. moderately hypoxic tumour total growth time (108 cells)
versus the symmetrical stem cell division probability (Spercent).
Figure 5: (a) The doubling time (TD), and (b) the total tumour
growth times, versus the symmetrical stem cell division probability
(Spercent) ranging from 2 to 30% for oxic and moderately hypoxic
simulations of tumour growth up to 108 cells. In Figure (a) the size
of the error bars are negligible.
cell type percentage on the Spercent parameter are shown in
Figure 4. The default value used for the Spercent parameter
(3%) results in a distribution of cell types that closely match
literature reports and a realistic statistically stable tumour
growth rate after 104 cells [38, 40, 62]. The tumour growth
characteristics for oxic and hypoxic tumours are displayed
in Figures 5(a) and 5(b). These tumour growth times (for
a small 0.5 to 1.0 cm diameter tumour mass) agree with
reported values of TD for head and neck cancers [40].
Note that hypoxia-related parameters are set to maintain the
distribution of cell types in the tumour throughout growth.
Experimental data relating to how the cell percentages
change when tumours are in a hypoxic state is diﬃcult to
obtain; therefore this eﬀect has not been considered.
The linked list method of data storage allows for flexible
and eﬃcient cell data storage and enables 108 cells to be
































Oxic tumour radiotherapy simulations
varying the beta parameter (β) in the α/β ratio (constant α = 0.3 Gy−1)
Figure 6: Comparison of the number of 2Gy fractions required in
the HYP-RT model to kill all basal or all stem cells compared to the
linear quadratic (LQ) model (the first fraction that achieves <1.000
cells remaining), for oxic tumour conventional radiotherapy.
propagated on a standard oﬀ-the-shelf computer. For oxic
tumour growth simulations the average computation time
is now less than fifteen minutes. For hypoxic tumours this
may be extended up to thirty minutes. Total tumour growth
times increase for hypoxic tumours due to the extracell
death and therefore a longer time was required to propagate
cells up to an equivalent tumour volume. Treatment-related
parameters, especially the Spercent and AR boost factor, also
alter the computation time because of their impact on stem
cell exponential growth and the reduction in (non-cycling )
cells.
3.2. The Dependence of Cell Kill on the Alpha/Beta Ratio. The
default α/β value in the model is 10Gy. However, results for
a range of α/β values help to verify that the model predicts
the same level of cell kill as LQ theory for oxic tumours
(Figure 6). In the comparison, α values were held constant
(0.3Gy−1) while the beta value was varied (from 0.1 to
0.015Gy−2), producing α/β values in the range of 3 to
20Gy. For this analysis basal cell elimination as well as the
elimination of stem cells only is considered. The stem cell
simulation results are in good agreement with the LQ model,
while results involving the cell kill of all basal cells are on
average 2 to 3 fractions higher.
3.3. Oxic Tumour Radiotherapy. A factor is used in HYP-RT
to increase the stem cell symmetrical division probability to
model accelerated repopulation (the AR boost factor). To
determine themost plausible AR boost factor, the onset times
of AR are varied from 3% to 15% and from 0 to 3 weeks,
respectively, and the consequential extra dose per fraction
is required to account for the extracell growth calculated
(Figure 7). Note that the increases in doses per fraction
shown in Figure 7 apply during the period of AR only
therefore the week of AR onset is not a critical parameter.
An AR boost factor value of 10 results in an extra dose
between 0.5 and 0.8Gy per fraction, which is consistent with
clinical trial reports [8, 63, 64]. An AR boost factor less than
10 increases the dose per fraction by 0.3Gy or less, while an
AR boost factor more than 10 results in an extra dose per
fraction above 1.0Gy. An AR boost factor of 10 was intuitively
expected to impact on tumour response in a biologically
plausible manner, as there have been reported increases in
tumour growth rate of up to 10 times (reducing the potential
doubling time (Tpot) from approximately 10 to 20 days down
to as low as 2 days [8, 65], approaching the stem cell division
time.
An AR boost factor of 10 decreases the tumour doubling
time after the onset of AR; for example, for moderately
hypoxic tumours the tumour doubling time decreases from
65 days down to 4.4 days after the onset of AR. Similarly for
oxic tumours, doubling times decrease from 37 days down to
3.7 days after the onset of AR (all standard deviation errors
<1 day). For moderately hypoxic tumours these doubling
times have good agreement with HNSCC published data [8].
3.4. Hypoxic Tumour Radiotherapy. Interfraction pO2 his-
tograms for a reoxygenating tumour are shown in Figure 8.
ROx events are initiated in simulations after the first dose
fraction in this example, with full ROx occurring by fraction
11. The model smoothly moves the peak of the histogram
curve to the right-hand side, to higher average pO2 levels,
simulating gradual ROx in the tumour, as desired.
Cells exhibiting very low oxygenation (pO2 < 1mmHg)
levels enter a hypoxia-induced quiescent state. The modelled
half-life of cells in this state does not impact significantly
on the number of fractions required to control the tumour;
however it does alter the timing of full ROx. Figure 9 shows
the impact of the hypoxic cell half life on cell kill and full ROx
timing when varied from 2 to 6 days.
The timing of ROx applied after completion of each
fraction of conventional therapy was analysed for the impact
on the total dose required to kill all cells. No significant
diﬀerence was found between applying ROx either 4 or
23 hours (just preceding the next daily fraction) after a
fraction. This result is expected since only conventional
treatments were simulated in this study, with 24 hours
between fractions. However, for future simulation work
involving alternate schedules (hyperfractionated schedules
with less than 2Gy per fraction), this may change since ROx
may occur during or after the next, same day fraction.
The eﬀects of AR on the dose per fraction required to
maintain total treatment times for hypoxic tumours were
also studied. During these calculations, 8 weeks is used
for the standard treatment time, as this is the treatment
time required in hypoxic tumour simulations with no AR
considered. The increase in dose per fraction (above the
standard 2.0Gy) is 0.5 to 0.9Gy using an AR boost factor
of 10 (Figure 10), closely matching oxic tumour results. The
dose per fraction required during AR to control the extracell
growth is relatively consistent for diﬀerent AR onset times
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Figure 7: The increase in dose per fraction (d/#) required during conventional radiotherapy of oxic tumours to account for accelerated

























pO2 histograms immediately after reoxygenation (ROx)
for a tumour programmed to begin ROx after fraction 1 of
radiotherapy (4-hour proceeding treatment)
Figure 8: Oxygenation (pO2) histograms after each fraction of
simulated conventional radiotherapy, ranging from fractions 1 to
8 of a moderately hypoxic tumour. In this example, treatment is
initiated when the tumour population has reached 108 cells and
hypoxic quiescent cells are reoxygenated above 1mmHg by fraction
number 11 (5×106 cells) and above 5mmHg by fraction 20 (5×105
cells).
(as it is in the oxic tumour study), because the dose increase
only applies after AR onset. With ROx simultaneously
considered, the dose per fraction reduces slightly but is still
approximately an extra 0.5Gy per fraction.
An AR boost factor of 10 is considered the most valid
value for this parameter based not only on the dose per
fraction study but also according to the decrease in tumour
doubling times predicted by the model; for example, the
tumour doubling time reduced to 1 to 5 days after onset of
AR compared with 35 to 65 days before onset of AR, with the
range depending on oxygenation status.
These results also indicate that the onset time of AR is
likely to be≤2 weeks if ROx occurs at≤2 weeks. However, the
onset time of AR could be >2 weeks if ROx also occurs late or
not at all (based on dose per fraction increases within 0.5 to
1.0Gy). Note that in all text and figures, error bars represent
standard deviations based on nine simulations per parameter
set. The statistical software package Prism 5 (v5.02, GraphPad
Software Inc.) and Microsoft Excel 2003 were used in the
analysis of the data.
4. Discussion
Onset times of ROx may be varied in the model from
zero (immediately after treatment initiation) to three weeks.
Immediate ROx is biologically possible because of the
reduced demand of oxygen arising from the death of the
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Oxic tumour status achieved
(onset of ROx at 0 weeks)
The impact of the hypoxia-induced quiescent cell half life
on moderately hypoxic tumour radiotherapy
Figure 9: A comparison of the average number of conventional
radiotherapy fractions with simulated reoxygenation (ROx) with
no accelerated repopulation, required for cell kill of moderately
hypoxic tumours when varying the half life of hypoxic quiescent
cells.
first lethally hit cells (some hours after the first fraction).
Variability of onset of ROx occurs because of other consid-
erations such as the structure of the vascular and supporting
tissues of the tumour and the dynamics of dead cell clearance
from the tumour mass. All of these factors are likely to vary
among patients, making the prediction of onset time of ROx
for a particular tumour especially challenging. The timing
of ROx events after each treatment fraction does not impact
on the final cell kill results for the simulated conventional
treatments in this study beyond the statistical error of the
algorithm. The impact was not expected to be significant
because all ROx events were programmed to occur before the
next daily fraction.
ROx is ideally modelled continuously throughout
tumour shrinkage. Modelling increases to cellular pO2 levels
at every hour of the radiotherapy regimen is computationally
exhaustive; therefore as a compromise, ROx events are
modelled after every daily dose fraction. Ideally, modelling of
ROx would also be based on human pre- and midtreatment
tumour oxygenation assay or imaging data, for example,
PET, CT, MRI, or US imaging methods; however such data
is not readily available for every patient. In the future more
data of this kind may become available through research
eﬀorts including stratification of patients in clinical trials
investigating tumour oxygenation dynamics. Trial outcomes
would be very useful for radiobiological modelling of
tumour treatment response; however they may never be able
to predict individual tumour oxygenation behavior for a
specific patient. At this stage, the model can provide quanti-
tative information about the relative importance of hypoxia
and reoxygenation during radiotherapy. Results highlight the
need to pursue research into techniques for noninvasively
and eﬃciently collecting individual tumour data for input
into oxygenation specific models.
Modelling the onset time of AR as early as zero weeks
is based on the hypothesis that the microscopic response of
tumour cell injury may start after the first radiative damage
event. This somewhat contradicts reports based on clinical
trial data of AR onset or kick-oﬀ times in the order of 2 to
5 weeks [8, 9, 11, 55, 65]. However, these reports are based
on large patient averages of total treatment time eﬀects and
results of which are not necessarily representative of when
AR is initiated at the microscopic level. Like ROx, AR onset
times are likely to vary from patient to patient; thus for this
study a range of onset times of 0 to 3 weeks is used.
Due to the complexity of biological factors required
in the model, it was necessary to make a number of
assumptions/limitations. The reduction of the cell cycle time
as an ARmechanism has been shown to have a significant but
relatively small eﬀect on tumour response; however this was
not modelled. It is likely that a number of these mechanisms
are induced together and are more significant if used in
combination [8, 25, 65, 66]. Abortive division of sterilised
stem cells (rather than diﬀerentiating) may also contribute to
repopulation of tissue after irradiation [67]. However, these
eﬀects are not as well understood, with limited studies in the
literature.
The radiotherapy eﬀect algorithm does not take into
account repair of radiation-induced cell damage; however
the modelling of cellular repair will be considered in future
work. Spatial information of the tumour cells was not taken
into account; however this was not a hindrance to the
current results which are concerned with homogeneous dose
delivery. For future spatial dose delivery application, such as
IMRT or dose painting, the modelling of specific hypoxic
subvolumes of hypoxia will be a necessary addition to the
model.
HYP-RT modelling methods vary from other recent
stochastic hypoxia and radiotherapy modelling methods,
involving individual cells or cell groups [20, 24, 68], because
the tumour oxygenation data required is simple and easily
input in the form of a pO2 histogram. The pO2 histogram
may also be manipulated during tumour growth (or treat-
ment) if required to model dynamic oxygenation eﬀects.
Current issues with this model and other models of
this kind include the requirement of data gained through
methods that are invasive for the patient; however this is
improving as imaging techniques and associated marker
drugs are being researched and trialled.
Possible current uses for the model include the study
of cellar kinetic mechanisms and observations of (i) the
relative diﬀerences in total doses required when AR and ROx
are onset at various times, (ii) the diﬀerences in the total
doses required for tumours of varying oxygenation levels,
and (iii) the prediction of the eﬀects of treatment breaks on
the extradose required to compensate for the break.
5. Conclusion
Due to the complexities and dynamic nature of tumour
oxygen and reoxygenation during radiotherapy, MC meth-
ods remain the most comprehensive and simplistic way of
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Figure 10: The increase in dose per fraction (d/#) required during conventional radiotherapy of moderately hypoxic tumours to account for
accelerated repopulation (AR), assuming a fixed total treatment time of 8 weeks and the increase in d/# coinciding with the onset of AR, for
various onset times of AR and ROx.
incorporating hypoxia into a tumour model. The HYP-RT
model builds upon previous tumour growth modelling work
and is capable of modelling radiation cell kill for tumours
comprised of up to 108 individual cells. Computational and
temporal eﬃciency has been improved compared to previous
model versions, with better use of memory space and more
eﬃcient selection and allocation of randomised parameters.
Simulations of tumour growth and radiotherapy treatment
can be performed in approximately thirty minutes or less.
The way in which tumour hypoxia has been modelled is
simple yet specific, enabling individual tumour data input in
the form of a pretreatment pO2 histogram.
The reoxygenation algorithm provides a method of
gradually altering the initially hypoxic tumour oxygenation
histogram throughout treatment, to model the process of
oxygenation increase for a hypoxic tumour. The accelerated
repopulation algorithm provides a method of increasing the
cell propagation rate, using a parameter that increases the
symmetrical stem cell division probability, with a factor
of ten found to be most suitable value based on a study
involving the increase in dose per fraction required to the kill
the extracell growth during conventional radiotherapy.
Future aims include eﬃciently modelling 109 cell virtual
tumours to provide an even larger individual cell-based
model and the conversion of the code into the more modern
C++ programming language. The model has already been
used to explore the conventional radiotherapy schedule for
hypoxic tumours [29] and will be reported on in the near
future regarding alternate radiation regimens for tumours of
diﬀerent oxygenation levels.
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